Skip to content
Ignota Labs logo — Ignota Labs rescues promising but failing drugs, bringing ne...

Ignota Labs

Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients.

Founded 2021 United Kingdom Cambridge, United Kingdom 18 employees Seed Total: $6.90M AI, Biotechnology +3

General Information

Company Name Ignota Labs
Founded Year 2021
Location United Kingdom Cambridge, United Kingdom
Employees 18
Industries AI, Biotechnology, Health Care +2
Funding Stage Seed
Business Model B2B, SaaS
Revenue Model Licensing, Subscription, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Ignota Labs. To contact Ignota Labs, visit ignotalabs.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ignota Labs compare?

A PDF of Ignota Labs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ignota Labs soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 04, 2026

Ignota Labs announced their participation at BIO-Europe in Cologne.

About Ignota Labs

Ignota Labs, headquartered in the United Kingdom and founded in 2021, is pioneering advancements in the pharmaceutical and health care industries using AI technology. Their mission, succinctly captured by their slogan, "Ignota Labs rescues promising but failing drugs," underscores their commitment to reviving abandoned drugs with untapped therapeutic potential.

Their core innovation, SAFEPATH©, is a proprietary AI model that leverages bioinformatics and cheminformatics data through deep learning. This approach addresses critical safety issues in drug trials, identifying toxicity mechanisms and optimizing therapeutic balance.

Recently, Ignota Labs secured a substantial $6.90M grant investment from notable investors such as Gaingels, Montage Ventures, AIX Ventures, Blue Wire Capital, and Modi Venture Partners. This funding bolsters their strategy to expedite treatment availability by converting failed trials into successful therapeutic solutions.

Business keywords: AI in Drug Discovery, Drug Safety Solutions, Clinical Trial Rescue, Bioinformatics, Cheminformatics, Deep Learning, Toxicity Prediction, Pharmaceutical Innovation, Therapeutic Effectiveness, Abandoned Drug Revitalization, Preclinical Trial Focus, Phase 1 and 2 Clinical Trials, Molecular Data Analysis

Services & Products

AI-driven drug discovery
Drug safety assessment
Rescuing failing drugs
Pipeline development
Mechanism-driven toxicity mitigation

Target Customers

Pharmaceutical companies Biotech firms Healthcare providers Research institutions Drug developers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $6.90M 5
Gaingels, Montage Ventures +3
01 Feb 2025
Seed Undisclosed 1
Sustainable Ventures
01 Dec 2022

Ignota Labs Alternatives & Competitors

View All Alternatives
Ignota Labs vs

We are dedicated to building software solutions that transform biomedical data into actionable insig...

Growth
71 employees
Biotechnology, Health Care
Ignota Labs vs

The experts in AI technology for drug discovery and development.

Series C
182 employees
AI, Analytics
Ignota Labs vs
Ro5
Ro5 United Kingdom

Bioactivity. De Novo Drug Discovery. ADMET. Knowledge Graph.

Seed
12 employees
AI, Biotechnology

FAQ About Ignota Labs

Ignota Labs rescues promising but failing drugs, bringing new life to abandoned projects and new hope to patients.
Ignota Labs was founded in 2021.
Ignota Labs is headquartered in Cambridge, United Kingdom.
Ignota Labs operates in AI, Biotechnology, Health Care, Life Sciences and Pharmaceutical. Its work centres on AI in Drug Discovery, Drug Safety Solutions, Clinical Trial Rescue and Bioinformatics. Its customers include Pharmaceutical companies, Biotech firms and Healthcare providers.
Ignota Labs has a B2B and SaaS business model. Its revenue comes from Licensing, Subscription and Service Fee.
Ignota Labs has approximately 18 employees.
Ignota Labs has completed 2 funding rounds, raising a total of $6.90M. The latest funding stage is Seed.
Ignota Labs offers: AI-driven drug discovery, Drug safety assessment, Rescuing failing drugs, Pipeline development, Mechanism-driven toxicity mitigation.
Top alternatives and competitors to Ignota Labs include Molecular Health, Partex.AI Technology, Ro5, AIGEN Sciences Inc., Certara. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ignota Labs and Molecular Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ignota Labs, https://bouncewatch.com/company/ignota-labs, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout